drugset / Trial / NCT01970059

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension

NCT01970059

Phase 3 Unknown 302 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus in Patients With Mild or Moderate Primary Hypertension

Timeline

Start
2013-10
Primary completion
2013-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 18 mg Oral
Subject Carvedilol Other / unclassified 72 mg Oral
Comparator Metoprolol Other / unclassified 47.5 mg Oral
Comparator Metoprolol Other / unclassified 190 mg Oral